The Fort Worth Press - Obesity drug maker Novo Nordisk posts strong profit

USD -
AED 3.67298
AFN 67.00035
ALL 89.797801
AMD 387.239637
ANG 1.802698
AOA 912.502293
ARS 992.745296
AUD 1.523136
AWG 1.7925
AZN 1.69719
BAM 1.794822
BBD 2.019547
BDT 119.529407
BGN 1.821379
BHD 0.376827
BIF 2897.5
BMD 1
BND 1.316601
BOB 6.911994
BRL 6.011097
BSD 1.000275
BTN 84.131412
BWP 13.300909
BYN 3.273378
BYR 19600
BZD 2.016151
CAD 1.39072
CDF 2843.999689
CHF 0.876301
CLF 0.034992
CLP 965.549879
CNY 7.178197
CNH 7.119295
COP 4416.5
CRC 511.425163
CUC 1
CUP 26.5
CVE 101.302105
CZK 23.671979
DJF 177.720227
DKK 6.961065
DOP 60.474978
DZD 133.821047
EGP 49.196904
ERN 15
ETB 120.950438
EUR 0.933505
FJD 2.2569
FKP 0.765169
GBP 0.77734
GEL 2.714988
GGP 0.765169
GHS 16.402842
GIP 0.765169
GMD 71.502667
GNF 8629.999825
GTQ 7.719627
GYD 209.259429
HKD 7.774895
HNL 25.08011
HRK 6.88903
HTG 131.623383
HUF 383.785502
IDR 15876.35
ILS 3.743325
IMP 0.765169
INR 84.31815
IQD 1310
IRR 42092.497519
ISK 138.410108
JEP 0.765169
JMD 158.145895
JOD 0.709298
JPY 154.148497
KES 128.99971
KGS 86.201852
KHR 4074.999868
KMF 450.549418
KPW 899.999774
KRW 1401.32502
KWD 0.306898
KYD 0.833532
KZT 490.419381
LAK 21938.999767
LBP 89531.6677
LKR 293.117372
LRD 190.974981
LSL 17.379789
LTL 2.95274
LVL 0.60489
LYD 4.834979
MAD 9.794941
MDL 17.86455
MGA 4614.99988
MKD 57.502158
MMK 3247.960992
MNT 3398.000028
MOP 8.00624
MRU 39.900226
MUR 46.519751
MVR 15.410084
MWK 1735.494756
MXN 20.656596
MYR 4.403504
MZN 63.875004
NAD 17.369774
NGN 1671.989899
NIO 36.785005
NOK 11.12099
NPR 134.610443
NZD 1.680345
OMR 0.385005
PAB 1.000184
PEN 3.773498
PGK 4.010502
PHP 58.8815
PKR 277.893986
PLN 4.071025
PYG 7821.490516
QAR 3.6405
RON 4.643704
RSD 109.206028
RUB 98.363085
RWF 1365
SAR 3.756608
SBD 8.299327
SCR 13.619071
SDG 601.526387
SEK 10.887935
SGD 1.33446
SHP 0.765169
SLE 22.749428
SLL 20969.496802
SOS 570.99983
SRD 34.904962
STD 20697.981008
SVC 8.75203
SYP 2512.530268
SZL 17.370147
THB 34.262949
TJS 10.652473
TMT 3.5
TND 3.106502
TOP 2.342095
TRY 34.264198
TTD 6.784436
TWD 32.324503
TZS 2724.999722
UAH 41.484918
UGX 3672.570432
UYU 41.617341
UZS 12794.999864
VEF 3622552.534434
VES 43.402657
VND 25385
VUV 118.722039
WST 2.801184
XAF 601.96109
XAG 0.029645
XAU 0.000367
XCD 2.70255
XDR 0.749381
XOF 602.512179
XPF 109.550027
YER 249.825018
ZAR 17.75955
ZMK 9001.202138
ZMW 26.98082
ZWL 321.999592
  • RBGPF

    64.1700

    64.17

    +100%

  • CMSC

    0.0400

    24.68

    +0.16%

  • CMSD

    0.1200

    25.04

    +0.48%

  • SCS

    0.0700

    12.32

    +0.57%

  • RYCEF

    -0.0200

    7.28

    -0.27%

  • NGG

    1.0200

    65.47

    +1.56%

  • RIO

    0.4900

    65.5

    +0.75%

  • BCC

    4.2300

    138.49

    +3.05%

  • GSK

    0.0500

    37.02

    +0.14%

  • AZN

    -5.1600

    66.27

    -7.79%

  • JRI

    0.1700

    13.27

    +1.28%

  • VOD

    0.0900

    9.41

    +0.96%

  • RELX

    0.8500

    47.91

    +1.77%

  • BTI

    0.3500

    35.46

    +0.99%

  • BCE

    -0.2800

    28.84

    -0.97%

  • BP

    0.2300

    29.96

    +0.77%

Obesity drug maker Novo Nordisk posts strong profit
Obesity drug maker Novo Nordisk posts strong profit / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File

Obesity drug maker Novo Nordisk posts strong profit

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.

Text size:

Europe's most valuable company and the main driver of the Danish economy said it expected its 2024 full-year sales to be up by 23 to 27 percent from a year earlier, revising its earlier forecast of 22 to 28 percent.

It cited in a statement "the expectation of continued volume growth and capacity limitations at some manufacturing sites."

The group reported a 21-percent rise in net profit to 27.3 billion kroner ($3.94 billion) for the July-to-September period.

Sales jumped by 22 percent to 60 billion kroner, slightly under analysts' expectations.

Novo Nordisk is ramping up its manufacturing sites to keep up with surging demand for its new generation of effective weight-loss treatments using semaglutides.

Sales of Wegovy, which has been approved for use to treat obesity in Britain, Denmark, France, Germany, Norway and the United States, rose by 42 percent in the first nine months of the year.

Wegovy was also approved for use in China in June.

Sales of the company's other semiglutide bestseller, Ozempic -- an injectable anti-diabetic treatment which has become popular for its slimming properties -- soared by 54 percent in the same period.

Obesity has escalated into a global health crisis, affecting 900 million people worldwide, including over 40 percent of Americans and nearly a quarter of Europeans.

It is a risk factor for developing diabetes, some forms of cancer and complications from other diseases, such as Covid.

Difficult to treat, it is costly for healthcare systems and while its causes can be lifestyle-related, it can also be influenced by genetics.

Novo Nordisk has a hold on 74 percent of the market for weight-loss treatments.

The World Obesity Federation predicts that by 2035, over half of the world's population will be overweight or obese and the global economic impact could then exceed $4 trillion a year.

T.Dixon--TFWP